| 曹国洪,王凯,李佳琪,叶圣利,陈卫飞,王文晶,胡文超.CalliSpheres®载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J].中国介入影像与治疗学,2018,15(1):42-46 |
| CalliSpheres®载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析 |
| Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in treatment of liver cancer patients |
| 投稿时间：2017-06-14 修订日期：2017-09-15 |
| DOI：10.13929/j.1672-8475.201706028 |
| 中文关键词: 化学栓塞,治疗性 肝肿瘤 有效性 安全性 |
| 英文关键词:Chemoembolization, therapeutic Liver neoplasms Efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 1194 |
| 全文下载次数: 830 |
| 中文摘要: |
| 目的 评估CalliSpheres®载药微球经动脉导管化疗栓塞（DEB-TACE）治疗肝癌患者的有效性及安全性。方法 连续纳入20例肝癌患者，均接受DEB-TACE治疗。疗效评价分为完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD），总有效率（ORR）为CR+PR/总例数×100%。结果 DEB-TACE治疗后患者ORR为80.00%（16/20），CR率为40.00%（8/20），PR率为40.00%（8/20），SD率为15.00%（3/20），PD率为5.00%（1/20）；单个肿瘤结节的ORR为81.58%（31/38），CR率为50.00%（19/38），PR率为31.58%（12/38），SD率为15.79%（6/38），PD率为2.63%（1/38）。DEB-TACE治疗后，患者的半年无复发生存率为85.00%，半年总体生存率为95.00%。患者仅出现疼痛、发热、恶心、呕吐等轻微不良反应。结论 CalliSpheres® DEB-TACE治疗肝癌可以达到较好的临床缓解率并有较好的安全性。 |
| 英文摘要: |
| Objective To evaluate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treatment of patients with liver cancer. Methods Totally 20 patients with liver cancer undergoing DEB-TACE treatment were enrolled. Clinical efficacy included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The overall response rate (ORR) was defined as proportion of patients achieved CR and PR. Results After treatment of DEB-TACE, the ORR, CR, PR, SD, and PD of patients were 80.00% (16/20), 40.00% (8/20), 40.00% (8/20), 15.00% (3/20), and 5.00% (1/20), respectively; while for single tumor nodule, the ORR, CR, PR, SD, and PD were 81.58% (31/32), 50.00 (19/38)%, 31.58% (12/38), 15.79% (6/38), and 2.63% (1/38), respectively. After the treatment of DEB-TACE, the relapse free survival rate in half year was 85.00%, and the overall survival rate was 95.00%. The adverse events of patients were mild pain, fever, nausea and vomiting. Conclusion CalliSpheres® DEB-TACE is an effective and well tolerated treatment in liver cancer patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
